Gould Capital’s Biogen BIIB Stock Holding History

Gould Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$411	–	217
2025 Q1	$411	Hold	3	–	–	﹤0.01%	206
2024 Q4	$459	Buy	+3	New	+$506	﹤0.01%	206

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gould Capital's BIIB Position: Q2 2025 in Review

Gould Capital sold out of Biogen (BIIB) in Q2 2025, closing a stake of 3 shares — an estimated $411 sold.

Gould Capital first reported a position in BIIB in Q4 2024 and held it in 2 quarters. The position peaked at $459 in Q4 2024. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

Gould Capital reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
Gould Capital sold 3 Biogen shares in Q2 2025, an estimated $411.
Gould Capital first reported a position in Biogen in Q4 2024 and held it in 2 quarters.
Gould Capital's Biogen position peaked at $459 in Q4 2024.
866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on Gould Capital's 13F filing for Q2 2025, filed 14 Aug 2025.